Form 8-K

8-K — DataMeds AI, Inc.

Accession: 0001493152-26-047711

Filed: 2026-10-20

Period: 2026-10-19

CIK: 0002030763

SIC: 5122 (WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES)

Item: Regulation FD Disclosure

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1img01.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0002030763

2026-10-19

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

DC 20549

FORM

8-K

CURRENT

REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act Of 1934

Date

of Report (Date of earliest event reported): October 19, 2026

DATAMEDS

AI, INC.

(Exact

name of registrant as specified in its charter)

Delaware

001-42530

93-3264234

(State

or other jurisdiction

incorporation)

(Commission

File

Number)

(IRS

Employer

Identification

No.)

3000

Bayport Drive, Suite 950, Tampa, FL

33607

(Address of Principal Executive

Offices)

(Zip Code)

Registrant’s

telephone number, including area code: 844-203-6092

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions (see General Instruction A.2. below):

☐

Written communications

pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant

to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications

pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications

pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common Stock, $0.0001

par value

MEDS

The Nasdaq Capital Market

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2

of the Securities Exchange Act of 1934.

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

October 20, 2026, DataMeds AI, Inc. (the “Company”) issued a press release announcing it has regained compliance with Nasdaq

Listing Rule 5550(b)(1). The press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

Item 8.01 Other Events.

previously disclosed on Form 8-K/A filed on April 21, 2026, on April 13, 2026, the Company received a deficiency letter (the “Deficiency

Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”)

notifying the Company that, based on the stockholders’ equity of $(12,447,801) reported in the Company’s Annual Report on

Form 10-K for the fiscal year ended December 31, 2025, the Company no longer satisfied the $2,500,000 minimum stockholders’ equity

requirement for continued listing on The Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(b)(1), and that, as of the date

of the Deficiency Letter, the Company also did not meet the alternative compliance standards under that Rule based on market value of

listed securities or net income from continuing operations.

October 19, 2026, the Company received written notice from the Staff informing the Company that it has regained compliance with Nasdaq

Listing Rule 5550(b)(1).

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit

No.

Description

of Exhibit

99.1

Press Release dated October 20, 2026

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its

behalf by the undersigned hereunto duly authorized.

DataMeds AI, Inc.

Date: October 20, 2026

By:

/s/ Prashant

Patel

Prashant Patel, President

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit 99.1

PRESS RELEASE

DATAMEDS

AI, INC. (DBA DATAMEDS SI)

3000

BAYPORT DRIVE, SUITE 950

TAMPA, FLA. 33607

www.datamedsai.com

RUBENSTEIN PUBLIC RELATIONS

CONTACT: JAMES LAMBERT 212-805-3024

JLAMBERT@RUBENSTEINPR.COM

FOR

IMMEDIATE RELEASE

DATAMEDS

REGAINS COMPLIANCE WITH NASDAQ LISTING STANDARDS

Tampa,

Fla. – Tuesday, October 20, 2026 – DataMeds AI, Inc. (NASDAQ: MEDS) (“DataMeds AI,” “DataMEDS

SI,” “DataMEDS,” or the “Company”), a healthcare company leveraging its Health IT and physical infrastructure

together with its super intelligence (artificial intelligence) platform EinsteinRx™ and smart contracts platform PharmacyChain™,

today announced that it has received a notification letter (the “Compliance Notice”) from the Listing Qualifications Staff

of the Nasdaq Stock Market, LLC (“Nasdaq”) dated October 19, 2026, informing DataMEDS that it has regained compliance with

Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”). In order to regain compliance with the Equity Rule, DataMEDS needed to

have a minimum stockholders’ equity of $2.5 million.

The

Company originally received a notice of delisting from NASDAQ on April 13, 2026 outlining the basis for delisting proceedings:

1) Failure

to meet minimum $1.00 bid-price; and

2) Failure

to maintain a minimum of $2,500,000 in stockholder’s equity.

NASDAQ

notified the Company on June 9, 2026 that it had regained bid-price compliance and provided the Company additional time to attempt to

regain compliance with the minimum stockholders’ equity requirement.

Based

on a Company Form 8-K filing on October 13, 2026 that confirmed the Company’s stockholder’s equity exceeded $2,500,000 and

a subsequent Form 8-K filing on October 16, 2026 that provided additional details on the material events that resulted in the Company

exceeding $2,500,000 in stockholders’ equity, on October 19, 2026 NASDAQ confirmed that the Company was in compliance with the

Equity Rule. If the Company fails to evidence compliance upon filing its next periodic report it may be subject to delisting.

For

more information, visit www.datamedsai.com or contact James Lambert, Vice President at Rubenstein Public Relations, at jlambert@rubensteinpr.com

or at 212-805-3024.

-1-

About

DataMeds AI, Inc. (DBA DataMeds SI)

DataMeds

SI (NASDAQ: MEDS) is a healthcare company that focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and

telemedicine business units through its Health IT platforms to deliver a better experience for consumers and providers. Headquartered

in Tampa, Fla., DataMEDS incorporates the super intelligence platform EinsteinRx™ and blockchain-enabled smart contracts platform

PharmacyChain™ into the Health Lives Here mobile application, and its Corexa Pharmacy provides pharmacy dispensing and related

services, including the distribution of products developed by Tollo Health. DataMEDS has licensed patented GLP-1 patient management technology

from REBOOT, a subsidiary of Data Health Partners. The Company’s Helomics Corporation subsidiary operates a CLIA-certified laboratory

in Pittsburgh offering the ChemoFx® Assay.

Forward-Looking

Statements

This

press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements

are based on management’s current expectations and are not predictions of actual performance. Forward-looking statements include,

without limitation, the Company’s anticipated business strategy, operating plans and growth opportunities; the Company’s

ability to maintain compliance with Nasdaq listing standards; the Company’s liquidity, capital resources and ability to fund operations;

the Company’s ability to maintain compliance with Nasdaq listing standards, the development of a proprietary blockchain and the

development of provider-network features, the creation of the Health Lives Here pharmacy network, the success of the NFL Alumni Health

partnership, the companies’ proposed transaction with DataVault AI Inc. (NASDAQ: DVLT), Scilex Holding Company, EOS Holdings and

HealthBridge Advisors (controlling shareholder of Tollo Health, LLC); the satisfaction or waiver of closing conditions applicable to

any of the foregoing; the receipt of stockholder approval and any other required approvals; the Company’s anticipated business

strategy, operating plans and growth opportunities; the integration of telemedicine, pharmacy, laboratory, wearable-device, artificial

intelligence, blockchain and data-management technologies; the proposed development, commercialization and expansion of EinsteinRx AI,

PharmacyChain, Health Lives Here and related platforms; the anticipated growth of the market for Long COVID products and related treatment

approaches; the companies’ ability to empower patients to access, manage, control or monetize health data; the anticipated benefits

of the companies’ technology platforms, strategic relationships and business combinations; the Company’s capitalization,

outstanding securities, lock-up arrangements, public float and registration statements. Actual results may differ materially from those

expressed or implied in these forward-looking statements due to a number of risks and uncertainties, including those described under

“Risk Factors” in the Company’s most recent Annual Report on Form 10-K and subsequent filings with the Securities and

Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the

date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, except as required

by law.

DataMeds

AI Media Contact

James

Lambert, Vice President

Rubenstein

Public Relations

Phone:

212.805.3024

Email:

jlambert@rubensteinpr.com

DataMeds

AI Investor Contact

Investor

Relations: IR@datamedsai.com

###

-2-

GRAPHIC

Filename: ex99-1img01.jpg · Sequence: 3

Binary file (18600 bytes)

Download ex99-1img01.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.3

Cover

Oct. 19, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Oct. 19, 2026

Entity File Number

001-42530

Entity Registrant Name

DATAMEDS

AI, INC.

Entity Central Index Key

0002030763

Entity Tax Identification Number

93-3264234

Entity Incorporation, State or Country Code

Entity Address, Address Line One

3000

Bayport Drive

Entity Address, Address Line Two

Suite 950

Entity Address, City or Town

Tampa

Entity Address, State or Province

Entity Address, Postal Zip Code

33607

City Area Code

844

Local Phone Number

203-6092

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $0.0001

par value

Trading Symbol

MEDS

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration